CYTK - Cytokinetics, Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
CYTK price evolution
CYTK
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $119.98 | $113.02 | $99.69 | |
| Short term investments | $498.99 | $501.8 | $439.55 | |
| Net receivables | $0.83 | $1.28 | $2.5 | |
| Inventory | ||||
| Total current assets | $1067.81 | $638.7 | $628.05 | $561.42 |
| Long term investments | $15.38 | $40.53 | $15.47 | |
| Property, plant & equipment | $142.94 | $146.19 | $147.74 | $155.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $169.38 | $196.26 | $179.2 | |
| Total investments | $514.36 | $542.33 | $455.01 | |
| Total assets | $1523.79 | $808.08 | $824.32 | $740.61 |
| Current liabilities | ||||
| Accounts payable | $9.47 | $12.97 | $21.51 | $13.8 |
| Deferred revenue | ||||
| Short long term debt | $29.75 | $27.97 | $17.24 | |
| Total current liabilities | $102.78 | $88.86 | $102.68 | $77.72 |
| Long term debt | $643.43 | $725.17 | $727.8 | $731.24 |
| Total noncurrent liabilities | $1115.39 | $1107.96 | $1101.69 | |
| Total debt | $754.92 | $755.77 | $748.47 | |
| Total liabilities | $1415.24 | $1204.24 | $1210.64 | $1179.41 |
| Shareholders' equity | ||||
| Retained earnings | -$2391.2 | -$2247.88 | -$2112.24 | -$1975.34 |
| Other shareholder equity | -$1.02 | -$0.54 | -$0.01 | -$0.87 |
| Total shareholder equity | -$396.16 | -$386.32 | -$438.8 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.02 | $65.58 | $112.67 | $82.98 |
| Short term investments | $501.8 | $717 | $358.97 | $381.07 |
| Net receivables | $1.28 | $0.15 | $51.82 | $4.42 |
| Inventory | ||||
| Total current assets | $628.05 | $795.19 | $535.67 | $474.22 |
| Long term investments | $40.53 | $46.71 | $152.05 | $36.95 |
| Property, plant & equipment | $147.74 | $163.19 | $146.41 | $22.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $196.26 | $219.59 | $305.65 | $59.58 |
| Total investments | $542.33 | $763.7 | $511.02 | $418.03 |
| Total assets | $824.32 | $1014.77 | $841.32 | $533.8 |
| Current liabilities | ||||
| Accounts payable | $21.51 | $25.61 | $21.09 | $8.05 |
| Deferred revenue | $87 | $87 | ||
| Short long term debt | $27.97 | $12.83 | $14.86 | $2.79 |
| Total current liabilities | $102.68 | $84.62 | $71.86 | $31.2 |
| Long term debt | $727.8 | $610.62 | $255.07 | $136.15 |
| Total noncurrent liabilities | $1107.96 | $1038.06 | $525.6 | $389.22 |
| Total debt | $755.77 | $749.34 | $269.93 | $138.94 |
| Total liabilities | $1210.64 | $1122.67 | $597.46 | $420.42 |
| Shareholders' equity | ||||
| Retained earnings | -$2112.24 | -$1585.99 | -$1207.62 | -$992.31 |
| Other shareholder equity | -$0.01 | -$3.59 | -$0.87 | $0.15 |
| Total shareholder equity | -$386.32 | -$107.9 | $243.86 | $113.38 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.83 | $1.67 | $0.38 | $0.87 |
| Cost of revenue | ||||
| Gross Profit | $0.83 | $1.67 | $0.38 | $0.87 |
| Operating activities | ||||
| Research & development | $81.57 | $84.98 | $82.53 | $83.19 |
| Selling, general & administrative | $45.5 | $44.11 | $40.11 | $39.72 |
| Total operating expenses | $127.07 | $129.09 | $122.64 | $122.92 |
| Operating income | -$126.23 | -$127.42 | -$122.27 | -$122.05 |
| Income from continuing operations | ||||
| EBIT | -$128.54 | -$129.73 | -$122.29 | -$121.59 |
| Income tax expense | ||||
| Interest expense | $7.1 | $7.16 | $7.14 | $7.04 |
| Net income | ||||
| Net income | -$135.64 | -$136.9 | -$129.42 | -$128.64 |
| Income (for common shares) | -$135.64 | -$136.9 | -$129.42 | -$128.64 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.53 | $94.59 | $70.43 | $55.83 |
| Cost of revenue | ||||
| Gross Profit | $7.53 | $94.59 | $70.43 | $55.83 |
| Operating activities | ||||
| Research & development | $330.12 | $240.81 | $159.94 | $96.95 |
| Selling, general & administrative | $173.61 | $177.98 | $96.8 | $52.82 |
| Total operating expenses | $503.74 | $418.79 | $256.74 | $149.77 |
| Operating income | -$496.2 | -$324.2 | -$186.31 | -$93.94 |
| Income from continuing operations | ||||
| EBIT | -$497.94 | -$369.54 | -$198.87 | -$111.33 |
| Income tax expense | ||||
| Interest expense | $28.31 | $19.41 | $16.44 | $15.96 |
| Net income | ||||
| Net income | -$526.24 | -$388.95 | -$215.31 | -$127.29 |
| Income (for common shares) | -$526.24 | -$388.95 | -$215.31 | -$127.29 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$135.64 | -$136.9 | -$129.42 | -$128.64 |
| Operating activities | ||||
| Depreciation | $2.33 | $6.33 | $1.85 | $1.85 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.61 | $19.49 | $18.72 | $18.67 |
| Total cash flows from operations | -$129.51 | -$74.04 | -$96.2 | -$121.81 |
| Investing activities | ||||
| Capital expenditures | -$0.08 | -$0.22 | -$0.72 | |
| Investments | $32.64 | -$81.33 | $73.26 | $82.84 |
| Total cash flows from investing | $32.64 | -$81.41 | $73.04 | $82.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $123.17 | $169.02 | $4.44 | $5.69 |
| Net borrowings | -$0.93 | -$0.22 | -$0.22 | -$0.21 |
| Total cash flows from financing | $103.79 | $168.8 | $54.22 | $5.47 |
| Effect of exchange rate | $0.03 | -$0.02 | ||
| Change in cash and equivalents | $6.95 | $13.33 | $31.05 | -$34.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$526.24 | -$388.95 | -$215.31 | -$127.29 |
| Operating activities | ||||
| Depreciation | $11.89 | $5.81 | $2.28 | $1.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $72.06 | $47.85 | $26.83 | $17.62 |
| Total cash flows from operations | -$414.33 | -$299.52 | -$142.52 | $8.94 |
| Investing activities | ||||
| Capital expenditures | -$1.42 | -$11.34 | -$48.87 | -$11.05 |
| Investments | $240.67 | -$250.8 | -$98.91 | -$185.46 |
| Total cash flows from investing | $239.25 | -$262.13 | -$147.78 | -$196.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $182.69 | $17.54 | $319.98 | $231.97 |
| Net borrowings | -$0.86 | $332.25 | ||
| Total cash flows from financing | $221.32 | $516.17 | $319.98 | $234.12 |
| Effect of exchange rate | -$0.02 | |||
| Change in cash and equivalents | $46.22 | -$45.48 | $29.68 | $46.55 |
News
Fundamentals
| Market cap | $6.36B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 117.53M |
| Revenue | $3.75M |
|---|---|
| EBITDA | -$489.77M |
| EBIT | -$502.15M |
| Net Income | -$530.60M |
| Revenue Q/Q | -81.90% |
| Revenue Y/Y | N/A |
| P/E ratio | -11.98 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.69K |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.51 |
|---|---|
| ROA | -54.46% |
| ROE | N/A |
| Debt/Equity | -3.13 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.39 |
| Quick ratio | N/A |